Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment ~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism...

Glucagon-Like Peptide 1 (GLP-1) Agonist Market To Reach USD 21.2 Billion By 2032, Report By DataHorizzon Research Fort Collins, Colorado, April 08, 2024 (GLOBE NEWSWIRE) -- Growing cases of diabetes and obesity trigger the need for GLP-1 receptor agonists Type 2 diabetes and obesity represent critical health...

NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...